Conv-Swinformer: 整合CNN和转移窗口注意力用于阿尔茨海默氏症疾病分类
Zhentao Hu1, Yanyang Li1, Zheng Wang1
1School of Artificial Intelligence, Henan University, Zhengzhou, 450046, China.
Computers in biology and medicine
|August 7, 2023
概括
这项研究介绍了Conv-Swinformer,这是一种使用脑MRI扫描进行阿尔茨海默病 (AD) 预测的深度学习模型. 它通过专注于局部细节来增强特征提取,提高诊断准确性.
科学领域:
- 人工智能在医学中的应用
- 神经成像分析分析 神经成像分析
- 深度学习用于疾病预测和预测
背景情况:
- 使用脑MRI的深度学习 (DL) 模型在预测阿尔茨海默病 (AD) 中显示出高准确度.
- 变压器在计算机视觉中是有效的,但在3DMRI中对局部特征的平等待遇有所困难.
- 医疗图像数据集通常很小,这阻碍了捕获关键的局部病变特征.
研究的目的:
- 提出一种新的深度学习模型,Conv-Swinformer,用于在3DMRI中增强提取和集成局部细粒度特征.
- 通过专注于空间相关信息来提高阿尔茨海默病预测的准确性.
- 解决现有DL模型在处理局部特征重要性和小数据集大小方面的局限性.
主要方法:
- 开发了Conv-Swinformer,集成了CNN模块用于平面特征总结和转换器编码器用于3D空间语义连接.
- 在变压器编码器内实施了转移窗口注意力机制,以专注于局部MRI区域.
- 利用逐层扩大的注意窗口逐层整合当地的细粒度特征.
主要成果:
- Conv-Swinformer通过优先考虑相邻的声音信息,有效地提取局部病变特征.
- 转移窗口的注意力机制减少了背景噪声,提高了对相关图像区域的关注度.
- 该模型与无区别地融合本地特征的DL算法相比,实现了优越的分类结果.
结论:
- 通过精细的局部特征分析,Conv-Swinformer展示了通过精细的局部特征分析来准确预测阿尔茨海默病的巨大潜力.
- 尽管数据集的局限性,但拟议的架构提供了一个有效的解决方案,用于利用变压器在医学成像中的功能.
- 专注于细粒度的局部特征对于改善神经退行性疾病诊断中的深度学习模型性能至关重要.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
06:19Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction
Published on: August 16, 2024
448
相关概念视频
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
